Bioavailability of Reduced Coenzyme Q10 (Ubiquinol-10) in Burn Patients
Mitochondrial dysfunction has been implicated in the pathogenesis of inflammation and multi-organ dysfunction in major trauma, including burn injury. Coenzyme Q10 (CoQ10) is a metabolite of the mevalonate pathway and an essential cofactor for the electron transport in the mitochondria. In addition,...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/12/7/613 |
| _version_ | 1797417015396270080 |
|---|---|
| author | Naohide Kuriyama Tomoyuki Nakamura Harumasa Nakazawa Tyler Wen Lorenzo Berra Edward A. Bittner Jeremy Goverman Masao Kaneki |
| author_facet | Naohide Kuriyama Tomoyuki Nakamura Harumasa Nakazawa Tyler Wen Lorenzo Berra Edward A. Bittner Jeremy Goverman Masao Kaneki |
| author_sort | Naohide Kuriyama |
| collection | DOAJ |
| description | Mitochondrial dysfunction has been implicated in the pathogenesis of inflammation and multi-organ dysfunction in major trauma, including burn injury. Coenzyme Q10 (CoQ10) is a metabolite of the mevalonate pathway and an essential cofactor for the electron transport in the mitochondria. In addition, its reduced form (ubiquinol) functions as an antioxidant. Little is known as to whether oral CoQ10 supplementation effectively increases intracellular CoQ10 levels in humans. To study the bioavailability of CoQ10 supplementation, we conducted a randomized, double-blind, placebo-controlled study of reduced CoQ10 (ubiquinol-10) (1800 mg/day, t.i.d.) in burn patients at a single, tertiary-care hospital. Baseline plasma CoQ10 levels were significantly lower in burn patients than in healthy volunteers, although plasma CoQ10/cholesterol ratio did not differ between the groups. CoQ10 supplementation increased plasma concentrations of total and reduced CoQ10 and total CoQ10 content in peripheral blood mononuclear cells (PBMCs) in burn patients compared with the placebo group. CoQ10 supplementation did not significantly change circulating levels of mitochondrial DNA, inflammatory markers (e.g., interleukins, TNF-α, IFN-γ), or Sequential Organ Failure Assessment (SOFA) scores compared with the placebo group. This study showed that a relatively high dose of reduced CoQ10 supplementation increased the intracellular CoQ10 content in PBMCs as well as plasma concentrations in burn patients. |
| first_indexed | 2024-03-09T06:12:44Z |
| format | Article |
| id | doaj.art-8237cd931f2c49468bed50e97812cae8 |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-09T06:12:44Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-8237cd931f2c49468bed50e97812cae82023-12-03T11:56:56ZengMDPI AGMetabolites2218-19892022-07-0112761310.3390/metabo12070613Bioavailability of Reduced Coenzyme Q10 (Ubiquinol-10) in Burn PatientsNaohide Kuriyama0Tomoyuki Nakamura1Harumasa Nakazawa2Tyler Wen3Lorenzo Berra4Edward A. Bittner5Jeremy Goverman6Masao Kaneki7Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, 149 Thirteenth Street, Charlestown, MA 02129, USADepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, 149 Thirteenth Street, Charlestown, MA 02129, USADepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, 149 Thirteenth Street, Charlestown, MA 02129, USADepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, 149 Thirteenth Street, Charlestown, MA 02129, USADepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, 149 Thirteenth Street, Charlestown, MA 02129, USADepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, 149 Thirteenth Street, Charlestown, MA 02129, USADepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USADepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, 149 Thirteenth Street, Charlestown, MA 02129, USAMitochondrial dysfunction has been implicated in the pathogenesis of inflammation and multi-organ dysfunction in major trauma, including burn injury. Coenzyme Q10 (CoQ10) is a metabolite of the mevalonate pathway and an essential cofactor for the electron transport in the mitochondria. In addition, its reduced form (ubiquinol) functions as an antioxidant. Little is known as to whether oral CoQ10 supplementation effectively increases intracellular CoQ10 levels in humans. To study the bioavailability of CoQ10 supplementation, we conducted a randomized, double-blind, placebo-controlled study of reduced CoQ10 (ubiquinol-10) (1800 mg/day, t.i.d.) in burn patients at a single, tertiary-care hospital. Baseline plasma CoQ10 levels were significantly lower in burn patients than in healthy volunteers, although plasma CoQ10/cholesterol ratio did not differ between the groups. CoQ10 supplementation increased plasma concentrations of total and reduced CoQ10 and total CoQ10 content in peripheral blood mononuclear cells (PBMCs) in burn patients compared with the placebo group. CoQ10 supplementation did not significantly change circulating levels of mitochondrial DNA, inflammatory markers (e.g., interleukins, TNF-α, IFN-γ), or Sequential Organ Failure Assessment (SOFA) scores compared with the placebo group. This study showed that a relatively high dose of reduced CoQ10 supplementation increased the intracellular CoQ10 content in PBMCs as well as plasma concentrations in burn patients.https://www.mdpi.com/2218-1989/12/7/613coenzyme Q10ubiquinolburn injurybioavailability |
| spellingShingle | Naohide Kuriyama Tomoyuki Nakamura Harumasa Nakazawa Tyler Wen Lorenzo Berra Edward A. Bittner Jeremy Goverman Masao Kaneki Bioavailability of Reduced Coenzyme Q10 (Ubiquinol-10) in Burn Patients Metabolites coenzyme Q10 ubiquinol burn injury bioavailability |
| title | Bioavailability of Reduced Coenzyme Q10 (Ubiquinol-10) in Burn Patients |
| title_full | Bioavailability of Reduced Coenzyme Q10 (Ubiquinol-10) in Burn Patients |
| title_fullStr | Bioavailability of Reduced Coenzyme Q10 (Ubiquinol-10) in Burn Patients |
| title_full_unstemmed | Bioavailability of Reduced Coenzyme Q10 (Ubiquinol-10) in Burn Patients |
| title_short | Bioavailability of Reduced Coenzyme Q10 (Ubiquinol-10) in Burn Patients |
| title_sort | bioavailability of reduced coenzyme q10 ubiquinol 10 in burn patients |
| topic | coenzyme Q10 ubiquinol burn injury bioavailability |
| url | https://www.mdpi.com/2218-1989/12/7/613 |
| work_keys_str_mv | AT naohidekuriyama bioavailabilityofreducedcoenzymeq10ubiquinol10inburnpatients AT tomoyukinakamura bioavailabilityofreducedcoenzymeq10ubiquinol10inburnpatients AT harumasanakazawa bioavailabilityofreducedcoenzymeq10ubiquinol10inburnpatients AT tylerwen bioavailabilityofreducedcoenzymeq10ubiquinol10inburnpatients AT lorenzoberra bioavailabilityofreducedcoenzymeq10ubiquinol10inburnpatients AT edwardabittner bioavailabilityofreducedcoenzymeq10ubiquinol10inburnpatients AT jeremygoverman bioavailabilityofreducedcoenzymeq10ubiquinol10inburnpatients AT masaokaneki bioavailabilityofreducedcoenzymeq10ubiquinol10inburnpatients |